Idorsia’s aprocitentan improved key prognostic indicators in patients with difficult-to-control hypertension

• New analysis from landmark Phase 3 PRECISION trial published in the Journal of Hypertension highlights aprocitentan led to improvements in dipping pattern and BP load

• Findings reinforce the role of aprocitentan’s novel endothelin pathway mechanism in addressing significant medical need in difficult-to-control hypertension

Allschwil, Switzerland – November 10, 2025
Idorsia Ltd (SIX: IDIA) announced the publication of a new analysis from the landmark Phase 3 PRECISION study in the Journal of Hypertension titled “Effects of aprocitentan on prognostically relevant ambulatory blood pressure-derived variables in resistant hypertension”¹. The analysis examined the changes in variables derived from ambulatory BP monitoring that are shown to drive better outcomes for patients at high risk of cardiovascular events.

Aprocitentan (TRYVIO/JERAYGO), the first approved antihypertensive targeting the endothelin pathway, substantially lowered 24-hour blood pressure (BP) in patients with confirmed resistant hypertension, with particularly pronounced effects at night. Night-time BP is a strong indicator of poor long-term outcome. The new analysis shows that aprocitentan on top of at least triple anti-hypertensive therapy improved multiple characteristics of resistant hypertension that are linked to poor clinical outcomes, including reducing blood pressure load and normalizing night-time “dipping” patterns, and is efficacious in patients with increased arterial stiffness and salt sensitivity.

Markus Schlaich, MD, FAHA, FESC, ISHF, The University of Western Australia / Royal Perth Hospital and an investigator in the PRECISION study commented:
“Aprocitentan resulted in substantial and sustained improvements in ambulatory BP parameters which are predictive of cardiovascular risk. As a result, aprocitentan is positioned as a promising option that could reduce cardiovascular events and improve long-term outcomes in patients with resistant hypertension.”

Michael A. Weber, MD, preventative cardiologist and hypertension specialist at Downstate College of Medicine of the State University of New York, commented:
“The availability of aprocitentan in routine clinical practice is a welcome and much needed addition to our armamentarium to effectively treat a broad range of patients with difficult-to-control hypertension. It has the added benefit of targeting the otherwise unopposed yet highly relevant endothelin mechanism in the pathogenesis of hypertension, potentially yielding therapeutic effects beyond BP lowering per se.”